Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Zevra Therapeutics, Inc. (ZVRA:NASDAQ), powered by AI.
Zevra Therapeutics, Inc. is currently trading at $12.65. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Zevra Therapeutics, Inc. on Alpha Lenz.
Zevra Therapeutics, Inc.'s P/E ratio is 8.4.
“Zevra Therapeutics, Inc. trades at a P/E of 8.4 (undervalued) with strong ROE of 85.7%. 3Y revenue CAGR of 118.8% highlights clear growth momentum.”
Ask for details →Zevra Therapeutics Inc. is a pharmaceutical company specializing in the development and commercialization of innovative therapies. Its primary focus is on addressing unmet medical needs across a range of therapeutic areas. Zevra Therapeutics engages in delivering transformative medical solutions for patients through a robust pipeline of candidate drugs. The company places significant emphasis on rare and orphan diseases, seeking to bring life-changing treatments to those often overlooked in the broader medical landscape. Notable features of Zevra Therapeutics include its commitment to leveraging scientific expertise and advanced research methodologies to develop novel therapies. The company collaborates with a network of research institutions, healthcare professionals, and regulatory bodies to ensure the successful translation of scientific discovery into practical treatments. In the market, Zevra Therapeutics holds a pivotal role in contributing to pharmaceutical innovation and enhancing patient outcomes. Its efforts are vital in pushing the boundaries of traditional treatment paradigms, thereby fostering advancements in the medical field. With a strategic focus on impactful therapeutic areas, Zevra Therapeutics is positioned as a key contributor to the dynamic landscape of the life sciences industry.
“Zevra Therapeutics, Inc. trades at a P/E of 8.4 (undervalued) with strong ROE of 85.7%. 3Y revenue CAGR of 118.8% highlights clear growth momentum.”
Ask for details →Zevra Therapeutics, Inc. (ticker: ZVRA) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 59 employees. Market cap is $700M.
The current price is $12.65 with a P/E ratio of 8.41x and P/B of 4.52x.
ROE is 85.66% and operating margin is -3.98%. Annual revenue is $106M.